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Pseudomonas aeruginosa is an important cause of pulmonary infection in cystic fibrosis (CF). Its correct
identification ensures effective patient management and infection control strategies. However, little is known
about how often CF sputum isolates are falsely identified as P. aeruginosa. We used P. aeruginosa-specific
duplex real-time PCR assays to determine if 2,267 P. aeruginosa sputum isolates from 561 CF patients were
correctly identified by 17 Australian clinical microbiology laboratories. Misidentified isolates underwent
further phenotypic tests, amplified rRNA gene restriction analysis, and partial 16S rRNA gene sequence
analysis. Participating laboratories were surveyed on how they identified P. aeruginosa from CF sputum.
Overall, 2,214 (97.7%) isolates from 531 (94.7%) CF patients were correctly identified as P. aeruginosa. Further
testing with the API 20NE kit correctly identified only 34 (59%) of the misidentified isolates. Twelve (40%)
patients had previously grown the misidentified species in their sputum. Achromobacter xylosoxidans (n  21),
Stenotrophomonas maltophilia (n  15), and Inquilinus limosus (n  4) were the species most commonly
misidentified as P. aeruginosa. Overall, there were very low rates of P. aeruginosa misidentification among
isolates from a broad cross section of Australian CF patients. Additional improvements are possible by
undertaking a culture history review, noting colonial morphology, and performing stringent oxidase, DNase,
and colistin susceptibility testing for all presumptive P. aeruginosa isolates. Isolates exhibiting atypical phe-
notypic features should be evaluated further by additional phenotypic or genotypic identification techniques.
The accurate identification of Pseudomonas aeruginosa is a
critical component of cystic fibrosis (CF) patient management.
Once established within CF lungs, P. aeruginosa is rarely erad-
icated, leading to increased treatment requirements and an
accelerated decline in pulmonary function, quality of life, and
life expectancy (10, 13, 27). Emerging evidence indicates that
aggressive antipseudomonal therapy at the time of initial ac-
quisition may eliminate P. aeruginosa, preventing the develop-
ment of chronic infection for months or even years (37). Sim-
ilarly, separating patients with P. aeruginosa from other CF
patients may reduce the spread of multiple-antibiotic-resistant
strains capable of person-to-person transmission (16). Such
strategies are contingent upon the early and correct identifi-
cation of these organisms (30).
While there is much emphasis on misidentifying P. aerugi-
nosa as another species (39), less attention is paid to falsely
identifying other species as P. aeruginosa. Nevertheless, accu-
rate identification of P. aeruginosa is important, as this may
avoid prolonged and sometimes unnecessary antibiotic treat-
ments, which could select for other antibiotic-resistant patho-
gens (6). Similarly, in CF clinics where cohort isolation is
practiced as an infection control measure, false identification
could mean exposure of the CF patient to potentially trans-
missible bacteria (2, 17, 28, 33).
While most clinical strains of P. aeruginosa are easily iden-
tified, respiratory isolates from patients with CF can present a
taxonomic challenge (15, 24). Phenotypic identification of P.
aeruginosa from patients with CF is often complicated by slow
growth, auxotrophic metabolic activity, loss of pigment produc-
tion, multiple antibiotic resistance, atypical colonial morphol-
ogy, and development of mucoid exopolysaccharide (14, 25).
Commercial identification platforms are also considered unre-
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liable (18, 21, 39). Moreover, CF respiratory secretions may
contain other nonfermenting gram-negative bacilli, such as
Achromobacter, Stenotrophomonas, and Burkholderia species,
which can further impede the identification of P. aeruginosa
(29, 32, 35, 39).
Although several molecular strategies have been developed
recently (1, 35, 39), most clinical microbiology laboratories still
identify P. aeruginosa by traditional phenotypic techniques.
However, there are few published data describing the fre-
quency at which bacterial species in CF sputum are falsely
identified as P. aeruginosa by phenotypic methods. In this
study, we used P. aeruginosa-specific duplex real-time
(PAduplex) PCR assays, phenotypic analysis, amplified rRNA
gene restriction analysis (ARDRA), and partial 16S rRNA
gene sequence analysis to assess the rate and extent of mis-
identification of P. aeruginosa isolates in CF sputum by Aus-
tralian clinical microbiology laboratories.
MATERIALS AND METHODS
Study group and initial routine identification. This study was part of an
ongoing national multicenter prevalence study of P. aeruginosa clonal complexes
in Australian CF clinics and was approved by human research ethics committees
at each of the participating centers. Following informed consent, sputum samples
were collected from patients attending routine outpatient appointments and
during hospital admissions between September 2007 and September 2008.
Seventeen clinical microbiology laboratories servicing 10 large CF centers
participated in the study. Nine were located in the capital cities of five Australian
states, and another eight were in regional areas of one state (Table 1). The
laboratories were surveyed and asked to describe the phenotypic, and any ge-
notypic, methods they used to identify P. aeruginosa in CF sputum specimens.
For the purposes of this study, laboratory staff selected three P. aeruginosa
isolates cultured from each sputum specimen. Selection was based upon colony
morphology (nonmucoid versus mucoid). Isolates were identified in accordance
with local CF-related P. aeruginosa testing procedures. Overall, 561 CF patients
(416 adults aged18 years of age) provided 757 sputum specimens (188 patients
gave two specimens 6 months apart, and 8 patients provided a second specimen
after transfer to another center), from which 2,267 P. aeruginosa isolates were
selected. Until transportation to a research laboratory, the isolates were stored at
either 80°C in Protect vials (Oxoid Australia Pty. Ltd., Adelaide, Australia) or
room temperature on nutrient agar slopes.
Specimen processing. P. aeruginosa isolates were sent to one of two CF
microbiology research laboratories, where they were processed by one of three
scientists (T.K., K.R., and H.H.), using standardized techniques. Isolates were
subcultured onto nutrient agar (Oxoid Australia Pty. Ltd.), checked for purity,
and stored in 15% glycerol (Sigma-Aldrich Pty. Ltd., Castle Hill, Australia) at
80°C until being tested further.
As outlined in Fig. 1, following DNA extraction, each isolate underwent
PAduplex PCR (1). Isolates that produced amplicons for both PAduplex PCR
targets were categorized as P. aeruginosa. Those showing negative or discordant
PAduplex PCR results for the ecfX and gyrB targets had further testing by
phenotypic methods and ARDRA. Finally, isolates with discordant PAduplex
PCR results or those not reliably identified by ARDRA underwent partial 16S
rRNA gene sequence analysis.
FIG. 1. Algorithm for confirming Pseudomonas aeruginosa isolates.
API, analytical profile index; ARDRA, amplified rRNA gene restric-
tion analysis; NFGNB, nonfermenting gram-negative bacilli; PAduplex
PCR, Pseudomonas aeruginosa-specific duplex PCR.
TABLE 1. Submitting laboratory, number of isolates submitted, and
rates of misidentification for each participating laboratory
and CF center
Submitting
laboratorya
Location
of
laboratoryb
No. of
isolates
submitted
No. of
misidentifications
%
Misidentification
CF
centerc
A1 R 16 0 0.0 A
A2 R 9 0 0.0 A
A3 R 3 0 0.0 A
A4 R 3 0 0.0 A
A5 R 3 0 0.0 A
A6 R 3 0 0.0 A
A7 C 246 18 7.3d A
A8 R 3 0 0.0 A
A9 C 9 0 0.0 B
A10 C 864 15 1.7 C
A11 C 228 2 0.9 D/Ee
A12 R 63 0 0.0 B
B1 C 258 10 3.9 F
C1 C 99 6 6.1 G
D1 C 174 1 0.6 H
D2 C 72 0 0.0 I
E1 C 214 1 0.5 J
Total 2,267 53 2.3 10
a Letters denote different Australian states, and numbers denote different
clinical microbiology laboratories.
b R, laboratory located in a regional area of Australia; C, laboratory located in
a capital city of Australia.
c Letters denote different CF centers.
d API 20NE analysis of all potential P. aeruginosa isolates was initiated during
the study. The misidentification rate prior to regular API analysis (n  105
isolates, with eight negative results) was 7.6%; the misidentification rate after
introduction of regular API analysis (n 141, with 10 negative results) was 7.1%
(2  0.25; P  0.88).
e Represents two CF centers submitting isolates to a single microbiology lab-
oratory.
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DNA extraction. Bacterial isolates were suspended in 1 ml of 0.9% NaCl
(Baxter Healthcare, NSW, Australia) and centrifuged at 10,970  g for 3 min.
The supernatant was thereafter removed, and the pellet was resuspended in 200
l of 0.1 M Tris buffer (Sigma-Aldrich) and 40 l of 10 mg/ml lysozyme (Sigma).
Following incubation at 37°C for 1 hour, DNA from each lysate was extracted
using the DX Universal Liquid Sample CorProtocol on a CAS-1820 X-Tractor
gene instrument (Corbett Life Sciences, Sydney, Australia) as per the manufac-
turer’s instructions.
PAduplex PCR analysis. PAduplex PCR targeting the ecfX and gyrB genes was
performed on each isolate as described previously (1). Each 25-l reaction mix
comprised 12.5 l of Qiagen Quantitect probe master mix (Qiagen Pty. Ltd.,
Doncaster, Australia), 10 pmol of each primer (GeneWorks Pty. Ltd., SA, Aus-
tralia), 4 pmol of each TaqMan probe (GeneWorks Pty. Ltd., Hindmarsh, Aus-
tralia), and 2 l of DNA template. Thermal cycling and amplicon detection was
performed using an ABI Prism 7500 detection system (Applied Biosystems,
Scoresby, Australia).
ARDRA. ARDRA was performed as described previously (20, 34). Briefly,
each 25-l PCR mix contained 5 l of template DNA, 2.5 l of 10Qiagen PCR
buffer (Qiagen Pty. Ltd.), 1.5 mM MgCl2, a 20 mM concentration of each
deoxynucleoside triphosphate (GE Healthcare, Australia), 1 U of Taq DNA
polymerase (Qiagen Pty. Ltd.), 11.8 l of H2O, and 20 pmol (each) of the
oligonucleotide primers fD1 and rD1 (GeneWorks Pty. Ltd.). Thermal cycling
was performed in a Bio-Rad Mycycler personal thermal cycler (Bio-Rad Labo-
ratories Pty. Ltd., Gladesville, Australia). Restriction enzyme digestion (37°C for
1 hour) was performed using the enzymes DdeI and MspI (Roche Diagnostics
Australia Pty. Ltd., Castle Hill, Australia). Following agarose gel electrophoresis
(3% MS agarose [Roche Diagnostics Australia Pty. Ltd.] at 100 V for 60 min),
each isolate’s ARDRA profile was compared to those produced by a collection
of commonly encountered CF and related nonfermenting gram-negative control
strains (7, 20, 34). The control strain panel consisted of P. aeruginosa LMG 6395,
Stenotrophomonas maltophilia LMG 957, Achromobacter xylosoxidans LMG
1863, Burkholderia cepacia LMG 1222, Burkholderia multivorans LMG 18822,
Burkholderia stabilis LMG 14294, Burkholderia vietnamiensis LMG 18836, Burk-
holderia ambifaria LMG 19467, Burkholderia gladioli LMG 11626, B. gladioli
LMG 2121, Ralstonia pickettii LMG 5942, Ralstonia solanacearum LMG 2299,
Cupriavidus necator LMG 1199, Pandoraea norimbergensis LMG 18379, and
Inquilinus limosus wild type. Isolates that exhibited ARDRA profiles identical to
those of the control strains were identified as those particular species. Isolates
that exhibited an atypical ARDRA profile compared to the control strains were
analyzed by partial 16S rRNA gene sequencing.
Partial 16S rRNA gene sequencing. Initial 16S rRNA gene PCR primers,
reagents, and conditions were identical to those described for the ARDRA assay.
Sequencing PCR (i.e., forward and reverse) of the undigested amplicons was
performed using the oligonucleotide primers fD1 and rD1 (34) and the BigDye
Terminator v3.1 cycle sequencing kit (Applied Biosystems) according to the
manufacturer’s instructions. Postreaction cleanup was undertaken using the
Agencourt CleanSEQ sequencing purification system (Beckman Coulter Austra-
lia Pty. Ltd., Gladesville, Australia) according to the manufacturer’s instructions.
Capillary separation was achieved using an AB3730xl genetic analyzer (Applied
Biosystems).
16S rRNA gene sequences were compared with those available in the
GenBank, EMBL, and DDBJ databases. The overall quality of each sequence
was verified by Sequence Scanner v1.0 (Applied Biosystems) software, and se-
quence editing was performed using BioEdit Sequence Alignment Editor, ver-
sion 7.0.5.3. The identity of each edited sequence was analyzed with BLASTN.
Isolates were allocated to a genus and/or species if the sequence yielded a
similarity score of 98%.
Phenotypic identification. Bacterial isolates were tested with an API 20NE
V7.0 kit (bioMe´rieux Australia Pty. Ltd., Baulkam Hills, Australia) according to
the manufacturer’s instructions. Oxidase activity was checked with 1% tetra-
methyl p-phenylenediamine (Oxoid Australia Pty. Ltd., Osborne Park, Austra-
lia). Isolates that produced a violet to purple pigment within 10 to 15 s were
recorded as oxidase positive. False-positive reactions for oxidase-negative iso-
lates were also observed and recorded at 30 s. Interpretation of the oxidase and
API results was performed after 48 h of incubation, using APILAB PLUS
software (version 3.3.3). Pigmentation, colony characteristics (mucoid or non-
mucoid), and colistin susceptibility were also recorded for each isolate analyzed
by the API 20NE system. Susceptibility to colistin sulfate (Oxoid Australia Pty.
Ltd.) was determined following Clinical Laboratory Standards Institute disk
diffusion guidelines and interpretative breakpoints (8).
Retrospective analysis of patients with misidentified isolates. A retrospective
review of the respiratory culture history for each patient with an isolate misi-
dentified as P. aeruginosa was also performed. Patients were recorded as “pre-
viously infected with a misidentified isolate” if the misidentified species con-
firmed in this study had been found in their sputum within two previous years of
the study’s sample collection.
Statistical analysis. All patient-specific data were stored in a customized
database (Filemaker Pro Advanced 9.0v3; Claris Corporation, Santa Clara, CA),
and analysis was performed using SPSS, version 17.0 (SPSS Inc., Chicago, IL).
Comparison between categorical variables used 2 and Spearman correlation. A
two-tailed P value of 0.05 was considered statistically significant.
RESULTS
Study group and initial routine identification. Each partic-
ipating laboratory provided details of how they identified P.
aeruginosa isolated from CF sputum (Table 2). Eleven (65%)
laboratories used a combination of basic phenotypic traits, five
employed Vitek (1 or 2), and another introduced API 20NE
testing during the study. Thirteen laboratories reported using
Vitek (1 or 2) or API 20NE testing when atypical isolates were
encountered (isolates lacking phenotypic characteristics typical
of P. aeruginosa, such as colony morphology and growth at
42°C). Molecular identification of P. aeruginosa was not regu-
larly performed by any laboratory, although five reported its
application for atypical isolates.
PAduplex analysis. Of the 2,267 isolates, 2,209 (97.4%) were
confirmed as P. aeruginosa by PCR (both gyrB and ecfX targets
were present), leaving 5 (0.2%) with discordant results (only one
of the PCR targets detected) and 53 (2.3%) with negative results
(neither target identified) by the PAduplex PCR assay (Table 3).
Of the isolates that were negative for one or both of the PAduplex
PCR targets, no amplification product was detected.
Phenotypic analysis. Of the 58 isolates with discordant or
negative PAduplex PCR results, 39 (67%) had a positive oxi-
dase reaction within the prescribed 15 s (Table 3). False-pos-
itive reactions were seen for 8 (42%) of the 19 oxidase-negative
isolates. API results successfully identified (excellent to accept-
TABLE 2. Frequency and nature of methods used to identify
Pseudomonas aeruginosa by the 17 participating clinical
microbiology laboratories
Identification system
No. of laboratories
Routine usea Occasional useb
Oxidase activity 17
Colony morphology 17
Pigmentation 7
Growth at 42°C 11
Colistin susceptibility 4c
Previous culture history 2
Vitek 1 2 1
Vitek 2 3 3
API 20NE 1d 9e
Fluorescence on centrimide agar 1
C390 susceptibility 1 1
Chromogenic agar 2
Arginine hydrolysis 1
Fatty acid analysis 1
Molecular identification 5
a Routinely used to identify all potential P. aeruginosa isolates.
b Occasionally used when isolates lacked typical phenotypic features of P.
aeruginosa.
c CLSI disk diffusion testing was performed in three laboratories, and CLSI
agar dilution testing was used by one laboratory.
d Routine API 20NE use was initiated during the course of the study.
e Includes one laboratory which routinely used Vitek 2 for all potential isolates
and API 20NE testing when atypical isolates arose.
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able profiles) the following species in 38 (66%) isolates: A.
xylosoxidans, Mannheimia haemolytica/Pasteurella trehalosi, S.
maltophilia, B. cepacia, P. aeruginosa, Pseudomonas fluorescens,
Pseudomonas stutzeri, Pseudomonas luteola, Sphingomonas
paucimobilis, and Methylobacterium mesophilicum (Table 3).
Of the remaining 20 isolates, 1 had a very good identification
to the genus level and 19 had API results with low discrimina-
tion or doubtful or unacceptable profiles (Table 3).
TABLE 3. PAduplex PCR, API 20NE, ARDRA, and partial 16S rRNA gene sequencing results for the 58 isolates that were discordant or
negative by the PAduplex PCR assay
Group No. ofisolates
No. of
patients
Result
Final identificationPAduplexPCR Oxidasea API 20NE ARDRA Partial 16S rRNA genesequencing
gyrB ecfX
1 3 1    Alcaligenes faecalis (59.3%); low
discrimination level
A. xylosoxidans Not performed Achromobacter xylosoxidans
13 8    Achromobacter xylosoxidans (94.5%);
excellent or good identification
A. xylosoxidans Not performed Achromobacter xylosoxidans
1 1    Burkholderia pseudomallei (81.7%);
very good identification to the
genus level
A. xylosoxidans Not performed Achromobacter xylosoxidans
1 1    Mannheimia hemolytica/Pastuerella
trehalosi (92.9%); good
identification
A. xylosoxidans Not performed Achromobacter xylosoxidans
1 1    Pseudomonas stutzeri (76.0%);
doubtful profile
A. xylosoxidans Not performed Achromobacter xylosoxidans
1 1    Unacceptable profile A. xylosoxidans Not performed Achromobacter xylosoxidans
1 1    Comamonas testosteroni/
Pseudomonas alcaligenes (57.4%);
low discrimination level
A. xylosoxidans Not performed Achromobacter xylosoxidans
Total 21 14
2 5 3    Stenotrophomonas maltophilia
(99.9%); excellent or very good
identification
S. maltophilia Not performed Stenotrophomonas maltophilia
6 2    Stenotrophomonas maltophilia
(99.9%); doubtful profile
S. maltophilia Not performed Stenotrophomonas maltophilia
1 1    Unacceptable profile S. maltophilia Not performed Stenotrophomonas maltophilia
1 1    Weeksella virosa/Empedobacter brevis
(64.0%); low discrimination level
S. maltophilia Not performed Stenotrophomonas maltophilia
2 1    Stenotrophomonas maltophilia
(99.9%); excellent identification
Indeterminate Stenotrophomonas
maltophilia (100%);
815 bp
Stenotrophomonas maltophilia
Total 15 8
3 1 1    Burkholderia cepacia (99.9%); good
identification, possibility of
B. gladioli
P. aeruginosa Pseudomonas aeruginosa
(100%); 723 bp
Pseudomonas aeruginosa
2 1    Pseudomonas aeruginosa (97.9%);
acceptable identification
P. aeruginosa Pseudomonas aeruginosa
(100%); 787 bp
Pseudomonas aeruginosa
1 1    Unacceptable profile P. aeruginosa Pseudomonas aeruginosa
(100%); 782 bp
Pseudomonas aeruginosa
1 1    Pseudomonas aeruginosa (99.9%);
very good identification
P. aeruginosa Pseudomonas aeruginosa
(100%); 870 bp
Pseudomonas aeruginosa
2 1    Pseudomonas fluorescens (99.9%);
very good identification
Indeterminate Pseudomonas fluorescens/
synxantha/reactans
(100%); 827bp
Pseudomonas spp.
1 1    Pseudomonas stutzeri (99.2%); very
good identification
Indeterminate Pseudomonas mendocina
(100%); 793 bp
Pseudomonas mendocina
Total 8 6
4 1 1    Pseudomonas luteola (92.0%);
acceptable identification
Indeterminate Pantoea agglomerans
(100%); 867 bp
Pantoea agglomerans
4 2    Sphingomonas paucimobilis (96.8%);
good identification
I. limosus Not performed Inquilinus limosus
3 1    Rhizobium radiobacter (99.9%); very
good identification
Indeterminate Rhizobium radiobacter
(100%); 864 bp
Rhizobium radiobacter
2 1    Watersia paucula (47.6%); low
discrimination level
Indeterminate Cupriavidus respiraculi
(100%); 824 bp
Cupriavidus respiraculi
2 2    Unacceptable profile Indeterminate Serrata marcescens
(100%); 751 bp
Serrata marcescens
1 1    Burkholderia cepacia (99.9%);
excellent identification, possibility
of B. gladioli
B. gladioli Not performed Burkholderia gladioli
1 1    Methylobacterium mesophilicum
(84.5%); acceptable identification,
possibility of Ochrobactrum
anthropi
Indeterminate Ralstonia mannitolilytica
(100%); 803 bp
Ralstonia mannitolilytica
Total 14 9
a A positive oxidase test was recorded only if an isolate produced a violet to purple pigment within 10 to 15 s.
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Among the 58 isolates, 48 (74%) had nonmucoid colonies
and 10 had mucoid colonies. Thirty (52%) isolates had non-
mucoid and nonpigmented colony morphotypes. Thirteen iso-
lates exhibited yellow- or pale brown-pigmented nonmucoid
colonies; one mucoid and five nonmucoid colonies had green
pigmentation, while nine were nonpigmented mucoid colonies.
Ten (17%) isolates were resistant to colistin.
ARDRA. Of the 58 isolates analyzed by ARDRA, 44 (76%)
showed DdeI and MspI restriction patterns identical to those
of one of the control strains (Table 3). A. xylosoxidans (21
isolates), S. maltophilia (13 isolates), I. limosus (4 isolates), and
B. gladioli (1 isolate) were confirmed by ARDRA. All five
isolates with discordant PAduplex PCR results were identified
as P. aeruginosa. Overall, ARDRA failed to reliably identify 14
(24%) isolates.
16S rRNA gene sequencing. Partial 16S rRNA gene se-
quencing was performed on the 14 isolates with indeterminate
ARDRA profiles and the 5 discordant isolates by PAduplex
PCR assay (Table 3). The mean sequence length after manual
editing was 809 nucleotides (range, 723 to 870 nucleotides).
Seventeen of 19 (89%) isolates were identified to an indi-
vidual genus and species. Forward and reverse sequences ob-
tained from each of these isolates exhibited 100% homology
with those available in the GenBank, EMBL, or DDBJ data-
base, including sequences for the following species: S. malto-
philia, Cupriavidus respiraculi, Serratia marcescens, Ralstonia
mannitolilytica, Pseudomonas mendocina, Pantoea agglomerans,
and P. aeruginosa (Table 3). Two isolates with 100% homology
with sequences for P. fluorescens, Pseudomonas synxantha, and
Pseudomonas reactans were identified as Pseudomonas spp.
(Table 3).
Comparison of molecular and API 20NE analysis. API
20NE results for 34 (59%) of the 58 isolates were consistent
with ARDRA and/or partial 16S rRNA gene sequence analysis
(Table 3). Of the 38 isolates adequately identified by API
testing (excellent to acceptable profiles), only 29 (76%) were
confirmed by molecular testing. Altogether, just 13 (62%) A.
xylosoxidans and 7 (47%) S. maltophilia isolates were success-
fully identified by API testing. All four I. limosus isolates had
mucoid colonies and were misidentified by API testing as S.
paucimobilis (96.8%; good identification).
Final identification and evaluation of the misidentified iso-
lates. Virtually all (2,214/2,267 isolates [97.7%]) bacterial iso-
lates submitted by clinical microbiology laboratories were cor-
rectly identified as P. aeruginosa. Misidentification rates ranged
from 0.0% to 7.3% (Table 1) and were higher for laboratories
processing larger numbers of isolates for the study (r  0.88;
P  0.0001). Overall, 30 (19 adults) of the 561 (5.3%) CF
patients had isolates misclassified as P. aeruginosa. While all
adults were known to be chronically infected with P. aerugi-
nosa, for five children the culture results were falsely diagnosed
as a new P. aeruginosa infection. Of the 30 patients, 12 pro-
vided specimens on two separate occasions, although only 1 of
the 12 (8.3%) had isolates misidentified in both samples. Nev-
ertheless, when prior microbiology data for the 30 patients
were reviewed from the preceding 2 years, 12 (40%) had the
misidentified species cultured on at least one other occasion.
Table 3 shows that A. xylosoxidans (40%), S. maltophilia
(28%), and I. limosus (7.5%) were the most commonly misi-
dentified species. The other misidentified isolates were three
Rhizobium radiobacter isolates, two each of Pseudomonas spp.,
C. respiraculi, and S. marcescens, and one isolate each of B.
gladioli, P. mendocina, and P. agglomerans.
All A. xylosoxidans isolates had nonpigmented, nonmucoid
colony morphology and were oxidase positive and susceptible
to colistin. Each S. maltophilia isolate was oxidase negative
within the prescribed 10 to 15 s, although 53% had a false-
positive reaction at 30 s. Their colony morphology was non-
mucoid, with either yellow (n  9), pale brown (n  3), or no
(n  3) pigmentation. Thirteen (87%) S. maltophilia isolates
were susceptible to colistin. In contrast, all I. limosus isolates
produced highly mucoid, nonpigmented colonies, and along
with B. gladioli, R. mannitolilytica, and S. marcescens isolates,
they demonstrated resistance to colistin.
Of the misidentified isolates, 66% originated from labora-
tories relying predominantly upon basic phenotypic tests to
identify P. aeruginosa. These isolates included A. xylosoxidans
(n  15), S. maltophilia (n  11), R. radiobacter (n  3),
Pseudomonas spp. (n  2), and one each of B. gladioli, I.
limosus, P. mendocina, and P. agglomerans.
DISCUSSION
Identifying P. aeruginosa clinical isolates is usually straight-
forward and easily accomplished by simple phenotypic tests.
However, accurate identification of P. aeruginosa strains from
CF sputum is made difficult when chronic infection becomes
established, as strains undergo a series of phenotypic changes
during adaptation to the CF lung (14, 26). Furthermore, pa-
tients may harbor several other phenotypically similar species,
including A. xylosoxidans, S. maltophilia, Burkholderia spp.,
Ralstonia spp., Pandoraea spp., and I. limosus (14). Accurate
differentiation of these organisms can critically influence pa-
tient management (11, 35, 39). Several recent studies have
assessed the accuracy of identification practices for CF-related
nonfermenting gram-negative bacilli. However, most have fo-
cused upon either commercial and molecular assays or patho-
gens other than P. aeruginosa (4, 23, 32, 39).
The present study showed that when Australian clinical mi-
crobiology laboratories identified bacterial isolates from CF
sputum as P. aeruginosa, they were correct on almost 98% of
occasions. When the laboratories were wrong, the three most
common species misidentified as P. aeruginosa were A. xy-
losoxidans, S. maltophilia, and I. limosus. These three species
are regarded as emerging pathogens, although their patho-
genic role in CF lung disease is unclear and subject to contro-
versy, especially for patients already chronically infected with
P. aeruginosa (3, 9, 19, 31, 36, 38). Fortunately, none of the
misidentified bacteria included recognized gram-negative ba-
cillary CF pathogens from the B. cepacia complex (12). Nev-
ertheless, five children received arguably unnecessarily pro-
longed and aggressive antimicrobial therapy and may have
accidentally been exposed to patients infected with dominant
P. aeruginosa clonal complexes (2, 17, 28, 33, 37).
Recent reports highlight difficulties with using standard phe-
notypic identification techniques to differentiate P. aeruginosa
from A. xylosoxidans (9, 32). In the present study, misidentified
A. xylosoxidans isolates had a nonmucoid and nonpigmented
colony appearance and were susceptible to colistin. Provided
there was adherence to a stringent time interval, all S. malto-
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philia isolates detected in this study were oxidase negative.
False-positive oxidase reactivity among S. maltophilia isolates
has previously been implicated as contributing to misidentifi-
cation of B. cepacia complex isolates (5). Extracellular DNase
activity is another important phenotypic feature which can help
to differentiate this species from other gram-negative bacteria
(14). Therefore, stringent oxidase testing and testing for
DNase may reduce misidentification of S. maltophilia.
I. limosus has only recently been reported for a small num-
ber of patients with CF (3, 7, 38). Its phenotypic characteristics
include failure to grow on MacConkey agar, colistin resistance,
a predominantly mucoid colony appearance, growth on blood
agar at 42°C, and classification as either S. paucimobilis or
Agrobacterium radiobacter by API 20NE testing (7). The four
I. limosus isolates reported here had these features and exhib-
ited previously reported ARDRA profiles (7). These isolates
were collected from two female patients (aged 20 and 36 years)
whose forced expiratory volume in 1 s percent predicted
(FEV1%) values were 78.4 and 91.9%, respectively, in two
different centers. One patient was coinfected with P. aerugi-
nosa, Staphylococcus aureus, and Aspergillus fumigatus, and the
other was coinfected with P. aeruginosa. To our knowledge, this
is the first published account of this species in Australian CF
patients. Of interest, three of these isolates collected from one
patient were submitted by a laboratory which did not employ
routine colistin susceptibility testing. The introduction of rou-
tine colistin susceptibility testing and follow-up molecular
testing for resistant isolates may reduce misidentification of
I. limosus.
Molecular identification strategies for identifying CF-related
bacterial isolates have been reported previously (11, 29, 34,
39). In this study, PAduplex PCR provided definitive results
(concordant positive or negative results for both the ecfX and
gyrB targets) for 2,262 (99.8%) isolates. Of those with negative
results, all were subsequently confirmed by ARDRA and/or
sequencing to represent a genus and species other than P.
aeruginosa. The five isolates with discordant PAduplex PCR
results were all identified as P. aeruginosa. Reasons for the
incomplete reactivity of these isolates are unexplained, but we
intend to perform sequence analysis, as variation within
the ecfX and gyrB sequences may be responsible, highlighting
the importance of performing PCR assays targeted at multiple
genomic sites, thereby reducing the potential for false-negative
results (40).
API 20NE results for just over half of the misidentified
isolates were consistent with molecular testing results, confirm-
ing the inadequacies of commercial identification systems for
nonfermenting gram-negative bacilli (18, 21, 39). One labora-
tory that relied on oxidase testing, colony morphology, and
growth at 42°C introduced routine API 20NE analysis during
the study period, but this did not improve misidentification
rates.
A study strength was its prospective and multicenter design.
There were significant differences in misidentification rates
between large laboratories in capital cities and smaller regional
laboratories from a single state. Some of the differences are
likely to be related to differences in the numbers of samples
submitted for testing. The results, however, represent the
range of diagnostic accuracies in identifying P. aeruginosa iso-
lates from the sputa of CF patients in Australian clinical mi-
crobiology laboratories and are likely to be representative of
practices in this region. The study also has several limitations.
The primary focus was to investigate isolates identified by
clinical microbiology laboratories as P. aeruginosa. Isolates re-
ported as species other than P. aeruginosa were not submitted
and were outside the scope of the study. It is likely that some
P. aeruginosa isolates were misidentified as other species, but
this has been reviewed elsewhere (23, 32, 39). Second, selec-
tion of colonies for analysis by morphological criteria may have
introduced a sample bias, although this is likely to have been
minimized by the sample size. Third, we reviewed identifica-
tion procedures used by each laboratory, but this analysis did
not account for other factors which may impact misidentifica-
tion rates (e.g., time and resource constraints, local laboratory
staff experience, and numbers of staff handling the samples in
the clinical laboratories). Finally, all isolates that exhibited
positive PAduplex PCR results were identified as P. aeruginosa.
This study has not assessed the specificity of PAduplex PCR,
but in earlier work no cross-reactivity using the ecfX and gyrB
targets was noted (1, 22, 29).
To our knowledge, this study represents the most extensive
analysis of misidentification rates for P. aeruginosa isolates
collected from patients with CF. It demonstrated very low rates
of misidentification among P. aeruginosa isolates collected
from a broad cross section of CF patients, suggesting that most
isolates are accurately identified in the clinical laboratory. Fur-
thermore, within individual patients, microbiology laboratories
will often have previously identified the organism misdiag-
nosed as P. aeruginosa. In this study, A. xylosoxidans, S. malto-
philia, and I. limosus were the most commonly misidentified
species. Performance of culture history review, attention to
colony morphology, and undertaking stringent oxidase testing
and DNase and colistin susceptibility analysis should be con-
sidered for all presumptive P. aeruginosa isolates. Those iso-
lates exhibiting atypical phenotypic characteristics should be
evaluated further by additional phenotypic or genotypic iden-
tification techniques.
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